Gate2Brain is an early-stage biotech company that aims to improve drug delivery across biological barriers using an innovative peptide-based patented technology platform.
Using our technology, our goal is to provide improved permeable, non-antigenic, stable, receptor-specific, soluble, non-invasive, and cost-effective therapeutic candidates with potential applications in a large number of therapeutic fields.
WHY INVEST IN GATE2BRAIN
• An extensive patent portfolio protects our intellectual property rights.
• Our technology platform for the delivery of therapeutics is highly innovative.
• We target the treatment of rare diseases, such as pediatric solid tumors of the central nervous system (brain).
• We are supported by a highly prestigious board and leadership team.
• Our investor partners endorse our discipline in Capital Management.
• To become a world leading company using a cutting-edge delivery technology.
• To provide affordable health solutions.
• To recruit a bold, passionate, fearless and innovative team.
https://gate2brain.com/wp-content/uploads/2021/02/Ciència-al-Mercat-.png5681471Susana Meneseshttps://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.pngSusana Meneses2021-02-04 14:05:412021-03-08 17:23:36De la Ciència al Mercat (From Science to the Marketplace)
https://gate2brain.com/wp-content/uploads/2019/01/100tifiques-2021-banner.png6001200Susana Meneseshttps://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.pngSusana Meneses2021-01-21 17:14:202021-03-08 17:28:11Round Table in 100tífiques “Public Research and Research at Large Corporation”
https://gate2brain.com/wp-content/uploads/2021/01/News.jpg6481329Susana Meneseshttps://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.pngSusana Meneses2021-01-14 15:22:392021-03-17 16:02:34Gate2Brain co-signs its first article in ACS Publications under the title “Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma”
https://gate2brain.com/wp-content/uploads/2021/02/Sabadell-Prensa.jpg752987Susana Meneseshttps://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.pngSusana Meneses2020-12-29 13:17:572021-03-12 11:04:05BStartup of Banco de Sabadell invests in Gate2Brain biotech
https://gate2brain.com/wp-content/uploads/2021/02/Planta-Doce.jpg752987Susana Meneseshttps://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.pngSusana Meneses2020-11-24 17:14:452021-03-15 07:34:23Gate2Brain seeks up to 3 million euros to reach the clinical trial
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.
Where to find us
Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain firstname.lastname@example.org